Masataka Hayashi

Masataka Hayashi

Auto-generated profile, based on publicly available information

Masataka Hayashi

Johns Hopkins University 1 Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center Baltimore, Maryland

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 September 2024 in Cancer Research
Verified
Journal Article
Open access
PDF file
KOKoki Oyama
Koki Oyama
KNKohei Nakata
Kohei Nakata
CTChikanori Tsutsumi
Chikanori Tsutsumi
MHMasataka Hayashi
Masataka Hayashi
BZBo Zhang
Bo Zhang
MNMasafumi Nakamura
Masafumi Nakamura
The effect of immune checkpoint inhibitors is extremely limited in patients with pancreatic ductal adenocarcinoma (PDAC) due to the suppressive tumor immune microenvironment. Autophagy, which has been shown to play a role in antitumor immunity, has been proposed as a therapeutic target for PDAC. In this study, single-cell RNA sequencing of autophagy-deficient murine PDAC tumors revealed that autophagy inhibition in cancer cells induced dendritic cell (DC) activation. Analysis of human PDAC tumors substantiated a negative correlation between autophagy and DC activation signatures. Mechanistically, autophagy inhibition increased the intracellular accumulation of tumor antigens, which could activate DCs. Administration of chloroquine, an autophagy inhibitor, in combination with Flt3 ligand–induced DC infiltration inhibited tumor growth and increased tumor-infiltrating T lymphocytes. However, autophagy inhibition in cancer cells also induced CD8+ T-cell exhaustion with high expression of immune checkpoint LAG3. A triple-therapy comprising chloroquine, Flt3 ligand, and an anti-LAG3 antibody markedly reduced tumor growth in orthotopic syngeneic PDAC mouse models. Thus, targeting autophagy in cancer cells and activating DCs sensitize PDAC tumors to immune checkpoint inhibitor therapy, warranting further development of this treatment approach to overcome immunosuppression in pancreatic cancer. Significance: Inhibiting autophagy in pancreatic cancer cells enhances intracellular accumulation of tumor antigens to induce dendritic cell activation and synergizes with immunotherapy to markedly inhibit the growth of pancreatic ductal adenocarcinoma.

10 April 2020 in Surgical Case Reports
Verified
Journal Article
Open access
PDF file
TAToshiya Abe
Toshiya Abe
HSHiroshi Sakai
Hiroshi Sakai
MHMasataka Hayashi
Masataka Hayashi
SNSo Nakamura
So Nakamura
STShin Takesue
Shin Takesue
TNToru Nakano
Toru Nakano
Background: Intramural metastasis is rare in colorectal cancer, especially metastasis of ascending colon cancer to the appendix. Case presentation: A 64-year-old man was admitted to our hospital for surgery for ascending colon cancer detected by medical examination. Colonoscopy identified a type-2 tumor in the ascending colon, which was diagnosed as adenocarcinoma. Abdominal computed tomography revealed focal thickening of the ascending colon and middle of the appendix and swelling of the lymph nodes around the ileocolic artery. The patient underwent laparoscopic right hemi-colectomy with D3 lymph node dissection. Histopathological findings revealed that the ascending colon cancer was moderately differentiated adenocarcinoma with lymphatic and vascular invasion (stage IIIB; pT3N2M0). Additionally, moderately differentiated adenocarcinoma was observed mainly in the submucosa and muscularis propria of the appendix, which was approximately 10 cm proximal to the ascending colon cancer. These findings indicated intramural metastasis to the appendix from the ascending colon cancer. The patient experienced recurrence with lung metastasis 2.5 years after the first surgery. Conclusions: Intramural metastasis of ascending colon cancer to the appendix is extremely rare. Because the risk of recurrence and the prognosis for intramural metastasis has not been clarified, careful follow-up is recommended.

30 September 2025 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
YHYuto Hozaka
Yuto Hozaka
AMAnne Macgregor-Das
Anne Macgregor-Das
MHMasataka Hayashi
Masataka Hayashi
TYTakeichi Yoshida
Takeichi Yoshida
ABAmanda Blackford
Amanda Blackford
MGMichael Goggins
Michael Goggins
Background: Cancer antigen 125 (CA125) is widely recognized as a useful biomarker for the surveillance of patients with ovarian and other cancers. Prior genome-wide association studies have identified variants that influence CA125 levels. We evaluated the utility of stratifying CA125 levels by such variants and evaluated diagnostic performance in control subjects and patients with pancreatic ductal adenocarcinoma (PDAC). Methods: We measured CA125 levels in 807 control subjects and 450 patients with PDAC and genotyped 10 variants involving four genes (GAL3ST2, MSLN, D2HGDH, and MUC16). We compared CA125 levels in controls by variant and generated variant-defined CA125 cutoffs and then classified cases and controls into functional groups based on their variant profile. We used this variant classification to evaluate the diagnostic performance of CA125 in patients with PDAC. Results: Six variants associated with CA125 levels were used to group controls into one of four groups. Mean CA125 levels in the highest variant group were approximately fourfold higher than in the lowest group. African Americans were more likely to have a variant group associated with low CA125 levels. After setting diagnostic cutoffs by variant group, the diagnostic sensitivity of CA125 for PDAC was 20.2% at 98% specificity (areas under the ROC curve, 0.702), not significantly different from a uniform CA125 diagnostic cutoff (areas under the ROC curve, 0.700). Conclusions: Gene variants can be used to generate personalized CA125 reference ranges. This approach did not significantly improve CA125’s diagnostic performance for pancreatic cancer, but it merits evaluation in other diagnostic settings, such as detecting ovarian cancer. Impact: Gene variants can be used to personalize CA125 levels.

23 March 2026 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
AOAnn L. Oberg
Ann L. Oberg
WBWilliam R. Bamlet
William R. Bamlet
GIGrant Izmirlian
Grant Izmirlian
SBSeetharaman Balasenthil
Seetharaman Balasenthil
SBSurinder Kumar Batra
Surinder Kumar Batra
MGMichael Goggins
Michael Goggins
Purpose: The Pancreatic Cancer Detection Consortium (PCDC) performed a blinded Early Detection Research Network–defined phase II biomarker bakeoff study of blood-based biomarker panels. The aims were to evaluate panel performance, to compare the panels’ performance with that of cancer antigen 19-9 (CA19-9) alone, and to evaluate the performance of new combinations of the individual biomarkers. Experimental Design: Ten biomarkers representing eight biomarker panels and CA19-9 were evaluated using plasma, serum, and germline DNA from 140 stage I to IV pancreatic ductal adenocarcinoma (PDAC) cases and 140 controls from three tertiary care institutions, with controls frequency matched to cases on age and sex. LASSO regression was employed to explore new biomarker combinations. The primary metric was area under the receiver operating characteristic curve (AUC). Results: The study population was 51% female, with median age 67.3 (minimum: 45, maximum: 90) years. Biomarker panel AUCs ranged from 89.9 to 96.3; the AUC for serum CA19-9 alone was 91.7 [95% confidence interval (CI), 87.8–95.6]. Two panels had significantly higher AUCs than serum CA19-9 alone, the CA19-9/FUT2/3 panel (AUC = 96.3, P = 0.002), and the tissue factor pathway inhibitor/tenascin C (TFPI/TNC-FNIII-C) panel (AUC = 95, P = 0.01). Exploratory models to recombine biomarkers retained all but two biomarkers [optimism-corrected AUC = 96.4 (94–98.9)]. Conclusions: The CA19-9/FUT2/3 panel was the best performing panel in this biomarker bakeoff. Its evaluation in larger studies is warranted. Biomarker bakeoffs are an effective strategy for comparing the performance of promising biomarkers for pancreatic cancer early detection, and the PCDC is well poised to conduct such studies. Recommendations for performing such studies are provided.

17 June 2026
Verified
Other
Open access
KOKoki Oyama
Koki Oyama
KNKohei Nakata
Kohei Nakata
CTChikanori Tsutsumi
Chikanori Tsutsumi
MHMasataka Hayashi
Masataka Hayashi
BZBo Zhang
Bo Zhang
MNMasafumi Nakamura
Masafumi Nakamura
Top 30 DEGs for four DC clusters identified from scRNA-seq of CD45+ immune cells in KPC1 shNC / shATG7 syngeneic PDAC tumors

17 June 2026
Verified
Other
Open access
KOKoki Oyama
Koki Oyama
KNKohei Nakata
Kohei Nakata
CTChikanori Tsutsumi
Chikanori Tsutsumi
MHMasataka Hayashi
Masataka Hayashi
BZBo Zhang
Bo Zhang
MNMasafumi Nakamura
Masafumi Nakamura
Top 30 DEGs for three CD8+ T cell clusters identified from scRNA-seq of CD45+ immune cells in KPC1 shNC / shATG7 transplanted syngeneic PDAC tumors